



Cara Therapeutics  
Investor Relations Department  
107 Elm St. 9th Flr  
Stamford, CT 06902  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: CARA

Last Trade:	13.00
Trade Time:	4:00 PM ET Jan 19, 2018
Change:	0.56 <span style="color: green;">▲</span> (+4.502%)
Day Range	12.44 - 13.11
52-Week Range	11.11 - 28.50
Volume	1,105,022

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors.

We are developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. Our most advanced product candidate, intravenous, or I.V... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- Nov 8, 2017*  
[Cara Therapeutics to Present at November Investor Conferences](#)
- Nov 2, 2017*  
[Cara Therapeutics Reports Third Quarter 2017 Financial Results](#)
- Oct 31, 2017*  
[Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting](#)
- Oct 26, 2017*  
[Cara Therapeutics to Announce Third Quarter 2017 Financial Results on November 2, 2017](#)
- Oct 25, 2017*  
[Cara Therapeutics Doses First Patient in Phase 1 Study of Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients](#)

### Financials [\[ View all \]](#)

- Mar 10, 2017*  
[Annual Report \(10-K\)](#)
- May 10, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 2, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*  
[Quarterly Report \(10-Q\)](#)